Valuation: GENFIT

Market Cap 647M 739M 596M 553M 1.05B 70.5B 1.07B 7.14B 2.78B 34.61B 2.78B 2.71B 120B P/E 2025
-3.06x
P/E 2026 * 68.1x
Enterprise Value 593M 677M 546M 507M 962M 64.54B 975M 6.53B 2.54B 31.68B 2.54B 2.49B 110B EV / Sales 2025
2.34x
EV / Sales 2026 * 6.31x
Free-Float
86.88%
Yield 2025 *
-
Yield 2026 * -
1 day+27.62%
1 week+27.83%
Current month+22.48%
1 month+49.02%
3 months+71.93%
6 months+123.65%
Current year+145.19%
1 week 10.18
Extreme 10.18
12.86
1 month 8.41
Extreme 8.41
12.86
Current year 5.08
Extreme 5.075
12.86
1 year 3.01
Extreme 3.006
12.86
3 years 2.8
Extreme 2.8
12.86
5 years 2.74
Extreme 2.74
12.86
10 years 2.74
Extreme 2.74
33.76
Manager TitleAgeSince
Chief Executive Officer 58 15/09/2019
Director of Finance/CFO 52 21/04/2021
Chief Tech/Sci/R&D Officer - 26/11/2025
Director TitleAgeSince
Chairman 70 15/06/2017
Director/Board Member 54 14/09/1999
Director/Board Member 58 15/06/2017
Change 5-day change 1-year change 3-year change Capi.($)
+27.62%+27.83% - - 737M
+1.08%+7.56%+4.01%+9.84% 49.92B
+0.05%-1.78%+415.95%+622.14% 40.23B
-0.22%+6.91%+27.20%-5.06% 34.55B
+4.11%+6.94%+28.68%+63.70% 33.09B
-4.19%+6.03%+3.76%+32.17% 27.51B
-1.53%+2.43% - - 17.05B
+0.27%+4.60%+75.40%+139.05% 15.92B
-0.95%+0.76%+13.97%+21.59% 13.86B
+2.20%+3.73%+100.34%+100.43% 13.52B
Average +2.79%+5.72%+83.66%+122.98% 27.3B
Weighted average by Cap. +0.21%+6.43%+94.82%+140.89%

Financials

2025 2026 *
Net sales 66.82M 76.29M 61.54M 57.12M 108M 7.28B 110M 737M 287M 3.57B 287M 280M 12.39B 95.2M 109M 87.68M 81.39M 155M 10.37B 157M 1.05B 408M 5.09B 408M 399M 17.65B
Net income -8.3M -9.48M -7.65M -7.1M -13.48M -904M -13.66M -91.54M -35.62M -444M -35.6M -34.82M -1.54B 18.63M 21.27M 17.16M 15.93M 30.24M 2.03B 30.65M 205M 79.93M 996M 79.88M 78.12M 3.45B
Net Debt -54.72M -62.48M -50.4M -46.78M -88.84M -5.96B -90.04M -603M -235M -2.93B -235M -229M -10.14B -46.87M -53.51M -43.17M -40.07M -76.09M -5.1B -77.12M -517M -201M -2.51B -201M -197M -8.69B
Logo GENFIT
GENFIT is a biopharmaceutical company in late-stage development focused on the discovery and development of innovative therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, in particular due to a lack of approved treatments. GENFIT is a leading innovator in the field of nuclear receptor-based drug discovery with a rich history and a solid scientific heritage spanning nearly two decades. The company has offices in Lille, Paris, Zurich and Cambridge, MA (USA).
Employees
188
Date Price Change
06/07/26 12.86 +22.48%
03/07/26 €10.50 -6.91%
02/07/26 €11.28 +6.62%
01/07/26 €10.58 +0.76%
30/06/26 €10.50 +4.37%
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
12.94EUR
Average target price
14.00EUR
Spread / Average Target
+8.19%

Quarterly revenue - Rate of surprise